Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983540 | 0.87 | CHRM1 (0.43) | SLC1A3SLC1A2SLC1A1TDP1GABRR1 | |
| SCHEMBL4993740 | 0.84 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1TDP1GABRR1 | |
| SCHEMBL4983890 | 0.83 | CA2 (0.48) | SLC1A3SLC1A2SLC1A1TDP1ADRA1A | |
| SCHEMBL4618656 | 0.81 | TDP1 (0.43) | SLC1A3SLC1A2SLC1A1TDP1ADRA1A | |
| SCHEMBL4738608 | 0.78 | ACE (0.42) | SLC1A3SLC1A2SLC1A1TDP1GABRR1 | |
| SCHEMBL22636075 | 0.78 | ACE (0.42) | SLC1A3SLC1A2SLC1A1TDP1GABRR1 | |
| SCHEMBL4990636 | 0.78 | ACE (0.42) | SLC1A3SLC1A2SLC1A1TDP1GABRR1 | |
| SCHEMBL4983264 | 0.78 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1TDP1 | |
| SCHEMBL4991075 | 0.78 | CHRM1 (0.39) | SLC1A3SLC1A2SLC1A1TDP1GABRR1 | |
| SCHEMBL4986493 | 0.76 | CPB2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | claimed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | claimed |
| US-6306909-B1 | AMINOACID DERIVATIVES AND ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-23 | — | — | US | claimed |
| JP-2001515483-A | — | — | 2001-09-18 | — | — | JP | claimed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | claimed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6930112-B2 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-08-16 | — | — | US | disclosed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | disclosed |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | QUEEN'S UNIVERSITY AT KINGSTON AND NEUROCHEM, INC. | 2003-10-16 | — | — | US | disclosed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | disclosed |
| US-6306909-B1 | AMINOACID DERIVATIVES AND ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-23 | — | — | US | disclosed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | SLC1A3 118/4885SLC1A2 57/4885SLC1A1 106/4885 |
| US-20030229144-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | SLC1A3 90/4885SLC1A2 29/4885SLC1A1 88/4885 |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | SLC1A2, SLC1A1, SLC1A3 | SLC1A3 3/4885SLC1A2 1/4885SLC1A1 2/4885 |
| US-20020025949-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | SLC1A3 90/4885SLC1A2 29/4885SLC1A1 88/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | SLC1A3 128/4885SLC1A2 42/4885SLC1A1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.